Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME

被引：0
|
作者：
Jurisic-Erzen, D. [1 ]
Johansen, O. [2 ]
George, J. [3 ]
Mattheus, M. [3 ]
Zinman, B. [4 ,5 ]
Inzucchi, S. [6 ]
机构：
[1] Univ Hosp Ctr Rijeka, Rijeka, Croatia
[2] Boehringer Ingelheim Norway KS, Asker, Norway
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [21] Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?
    Strojek, Krzysztof
    Rokicka, Dominika
    Szymborska-Kajanek, Aleksandra
    Wrobel, Marta
    CLINICAL DIABETOLOGY, 2016, 5 (03): : 107 - 110
  • [22] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    George, Jyothis T.
    Johansen, Odd Erik
    Fitchett, David
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
  • [23] EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
    Perkovic, Vlado
    Levin, Adeera
    Wheeler, David
    Koitka-Weber, Audrey
    Mattheus, Michaela
    George, Jyothis
    von Eynatten, Maximilian
    Wanner, Christoph
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 12 - 12
  • [24] Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
    Kadowaki, Takashi
    Nangaku, Masaomi
    Hantel, Stefan
    Okamura, Tomoo
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (03) : 760 - 770
  • [25] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffrey
    Ofstad, Anne-Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina J.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
  • [26] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [27] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Al-Omran, Mohammed
    Inzucchi, Silvio E.
    Fitchett, David
    Hehnke, Uwe
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 137 (04) : 405 - 407
  • [28] EMPA-REG OUTCOME: consistent reduction in risk of cardiovascular (CV) outcomes and mortality with empagliflozin (EMPA) irrespective of sulphonylurea (SU) use at baseline
    George, J. T.
    Inzucchi, S. E.
    Fitchett, D.
    Mattheus, M.
    Janista, C.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S425 - S426
  • [29] Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Hantel, Stefan
    Woerle, Hans-Juergen
    Broedl, Uli C.
    von Eynatten, Maximilian
    Groop, Per-Henrik
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (11): : 2755 - 2769
  • [30] Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    CIRCULATION, 2020, 142
12345